Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL28960275 | 1.00 | CA5A (0.75) | — | |
| Sulfuric Acid SCHEMBL2849663 | 0.94 | CA5A (0.67) | — | |
| Sulfuric Acid SCHEMBL8398655 | 0.94 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL9059634 | 0.94 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL9390699 | 0.94 | — | — | |
| Sulfuric Acid SCHEMBL8656939 | 0.94 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL215504 | 0.94 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL626019 | 0.94 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL7873561 | 0.94 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL28862266 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125422-A1 | POLYMORPHIC FORMS OF CYCLO (-HIS-PRO) AND METHODS OF USE TO TREAT KIDNEY DISEASE | NOVMETAPHARMA CO., LTD. (KR) | 2026-05-07 | — | — | US | disclosed |
| US-12534496-B2 | Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease | NOVMETAPHARMA CO., LTD. (KR) | 2026-01-27 | — | — | US | disclosed |
| EP-4619020-A1 | COMPOSITION AND METHOD FOR PROLONG SURVIVAL OF TRANSPLANT AND RECIPIENT | NovMetaPharma Co., Ltd. (KR) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024161311-A1 | TREATMENT OF BETA-CELL FAILURE OR DYSFUNCTION | NOVMETAPHARMA CO., LTD. (KR) | 2024-08-08 | — | — | WO | disclosed |
| US-20240261366-A1 | TREATMENT OF BETA-CELL FAILURE OR DYSFUNCTION | NOVMETAPHARMA CO., LTD. (KR) | 2024-08-08 | — | — | US | disclosed |
| US-20240197816-A1 | COMPOSITION AND METHOD FOR PROLONG SURVIVAL OF TRANSPLANT AND RECIPIENT | NOVMETAPHARMA CO., LTD. (KR) | 2024-06-20 | — | — | US | disclosed |
| WO-2024121811-A1 | COMPOSITION AND METHOD FOR PROLONG SURVIVAL OF TRANSPLANT AND RECIPIENT | NOVMETAPHARMA CO., LTD. (KR) | 2024-06-13 | — | — | WO | disclosed |
| US-20240043472-A1 | POLYMORPHIC FORMS OF CYCLO (-HIS-PRO) AND METHODS OF USE TO TREAT KIDNEY DISEASE | NOVMETAPHARMA CO., LTD. (KR) | 2024-02-08 | — | — | US | disclosed |
| US-11820834-B2 | Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease | NOVMETAPHARMA CO., LTD. (KR) | 2023-11-21 | — | — | US | disclosed |
| US-20210061854-A1 | NOVEL POLYMORPHIC FORMS OF CYCLO (-HIS-PRO) | NOVMETAPHARMA CO., LTD. (KR) | 2021-03-04 | — | — | US | disclosed |